drugset
drugset / Trial / NCT05426369

A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

NCT05426369 ↗

Phase 1 Active not recruiting 36 enrolled Sichuan Clover Biopharmaceuticals, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Preliminary Efficacy and Pharmacokinetics of SCB-219M in the patients with chemotherapy-induced thrombocytopenia (CIT)

Timeline

Start
2022-06-14
Primary completion
2025-07-02
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein Protein / enzyme biologic 2 ug/kg Subcutaneous
Subject Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein Protein / enzyme biologic 15 ug/kg Subcutaneous

Indications

thrombocytopenia